Generic Medicine Info
Special Precautions
Patient with CV disease, long QT syndrome, history of ventricular arrhythmias, bradycardia, hypotension, hypertension, haematologic disorders (e.g. anaemia, leucopenia, thrombocytopenia), diabetes mellitus, hypoglycaemia, hyperglycaemia, hypocalcaemia, hypokalaemia, hypomagnesaemia, pancreatic disease, elevated amylase or lipase levels, asthma. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor ECG, blood pressure, LFTs, BUN, serum bilirubin, transaminases, renal function, blood glucose, serum electrolytes (e.g. K, Ca, Mg), haematologic status (e.g. CBC and platelets).
Adverse Reactions
Significant: Extravasation, ulcerations, tissue necrosis, hyperkalaemia, hypocalcaemia, hypomagnesaemia, hypertension, hypotension, ventricular tachycardia, QT prolongation, torsades de pointes, hyperglycaemia, pancreatic islet cell necrosis with hyperinsulinaemia, anaemia, leucopenia, thrombocytopenia; bronchospasm, cough, extrapulmonary infection with P. jirovecii. Gastrointestinal disorders: Nausea, vomiting, dysgeusia. General disorders and administration site conditions: Discomfort and pain to indurations, abcess formation, muscle necrosis. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Dizziness, syncope. Renal and urinary disorders: Renal insufficiency, azotaemia. Reproductive system and breast disorders: Shortness of breath, wheezing. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Flushing.
Potentially Fatal: Severe hypotension, hypoglycaemia, acute pancreatitis, cardiac arrhythmia.
Drug Interactions
Increased risk of arrhythmias with medicines that prolong QT interval (e.g. erythromycin, amiodarone, terfenadine, fluoroquinolones, phenothiazines, TCAs). Increased risk of hypocalcaemia with foscarnet. Increased risk of pancreatitis with didanosine, stavudine, zalcitabine. Increased risk of hyperkalaemia with K sparing diuretics.
Disclaimer: This information is independently developed by CIMS based on pentamidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in